SAN DIEGO, Aug. 9, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the second quarter ended June 30, 2012, and reviewed recent developments.
At June 30, 2012, cash and cash equivalents totaled $143.8 million, which does not include (i) the $20.0 million milestone payment received from Eisai Inc. subsequent to June 30 for the inclusion of the efficacy and safety data from the Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) clinical trial in patients with type 2 diabetes in the US Food and Drug Administration (FDA)-approved prescribing information for BELVIQ (lorcaserin hydrochloride); (ii) $23.4 million received subsequent to June 30 from the exercise of warrants and stock options; or (iii) $65.0 million for milestone payments that Arena is eligible to receive from Eisai following US Drug Enforcement Administration (DEA) scheduling designation and delivery of BELVIQ launch supply to Eisai.
"The FDA's approval of BELVIQ in the second quarter was a significant development for obese and overweight Americans who need help losing weight," said Jack Lief, Arena's President and Chief Executive Officer. "We are focused on working with Eisai to launch BELVIQ in the United States following the completion of DEA scheduling, and expect BELVIQ to play a key role in physicians' newly expanded toolkits for the medical management of obesity. We also have marketing authorization applications under review in the European Union and Switzerland, and are in the process of prioritizing our commercial and regulatory strategy for additional markets outside of the United States."
Recent BELVIQ (lorcaserin HCl) Developments
Other Recent Developments
Second Quarter 2012 Financial ResultsArena recorded revenues totaling $22.0 million in the second quarter of 2012, compared to $3.3 million in the second quarter of 2011, and $24.2 million in the first half of 2012, compared to $7.2 million in the first half of 2011. This increase was primarily the result of the $20.0 million milestone payment earned under the marketing and supply agreement with Eisai.
Research and development expenses continued to decline in the second quarter of 2012, decreasing to $14.1 million as compared to $14.7 million in the second quarter of 2011. Research and development expenses in the first half of 2012 declined to $28.5 million from $30.6 million in the first half of 2011, primarily due to decreased salary and other personnel costs. General and administrative expenses decreased to $5.2 million in the second quarter of 2012, compared to $6.1 million in the second quarter of 2011, and $11.6 million in the first half of 2012, compared to $13.0 million in the first half of 2011. These decreases were primarily due to lower patent legal fees.
Total interest and other expense increased to $30.9 million in the first half of 2012, compared to $17.6 million in the first half of 2011. This was primarily due to a $19.8 million increase in the non-cash loss from revaluation of derivative liabilities. Partially offsetting this expense increase was a $2.4 million decrease in interest expense, which resulted from prepayments on the Deerfield loan totaling $22.3 million, including the May 2012 payoff. Arena's net loss allocable to common stockholders in the first half of 2012 was $51.5 million, or $0.29 per share, compared to $65.1 million, or $0.49 per share, in the first half of 2011.
At June 30, 2012, approximately 205.1 million shares of common stock were outstanding and, due primarily to the exercise of warrants to purchase shares of common stock, approximately 216.8 million shares of common stock are outstanding today.
Updated 2012 Financial GuidanceArena also announced an update to its full year 2012 financial guidance. Arena increased its 2012 revenue guidance from $66-$72 million to $91-$97 million, which includes the $20.0 million milestone payment received from Eisai for the inclusion in the FDA-approved prescribing information of the BLOOM-DM data and, although the timing remains uncertain, $65.0 million for milestone payments that Arena will receive from Eisai following DEA scheduling designation and delivery of BELVIQ launch supply. If DEA scheduling and delivery of launch supply do not occur in 2012, revenue guidance would be $65.0 million lower. Guidance for research and development expenses of $57-$67 million, for general and administrative expenses of $20-$24 million and for capital expenditures of $2 million remains unchanged. Arena now expects to end 2012 with approximately $215 million in cash, cash equivalents and short-term investments. If DEA scheduling and delivery of launch supply do not occur in 2012, cash at the end of 2012 would be $65.0 million lower. 2012 revenue and end of year cash guidance do not include revenue or cash from product sales for BELVIQ or from Arena's entry into any new collaboration.
Scheduled Financial Results Call Arena will host a conference call and webcast to discuss the second quarter 2012 financial results and to provide a business and financial update today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Second Quarter 2012 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Upcoming Corporate PresentationsArena is planning to present at upcoming investment and industry conferences, including:
About BELVIQ (lorcaserin HCl)Lorcaserin hydrochloride is believed to decrease food consumption and promote satiety by selectively activating serotonin 2C receptors in the brain. Activation of these receptors may help a person eat less and feel full after eating smaller amounts of food.
Lorcaserin was approved by the FDA for chronic weight management under the trade name BELVIQ (pronounced "BEL-VEEK") in June 2012, and is currently under review for marketing approval in the European Union and Switzerland. Eisai Inc. has exclusive marketing and distribution rights in most of North and South America, and is preparing to launch BELVIQ in the United States. Arena continues to own marketing and distribution rights outside of North and South America, and has composition of matter patents issued in major jurisdictions globally that in most cases are capable of continuing into 2023 without taking into account any patent term extensions.
BELVIQ is indicated to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial BMI of:
Limitations of Use:
In clinical trials, the most common adverse reactions for patients without diabetes treated with BELVIQ were headache, dizziness, fatigue, nausea, dry mouth, and constipation. In patients with diabetes, the most common adverse reactions were hypoglycemia, headache, back pain, cough, and fatigue.
About Arena PharmaceuticalsArena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information about Arena, please visit www.arenapharm.com.
Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.
Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about lorcaserin's (or BELVIQ's) safety, efficacy, mechanism of action, DEA scheduling, commercial launch and potential; the significance of the FDA approval of BELVIQ; the use of BELVIQ by patients and physicians; rights, obligations and expectations related to the marketing and supply agreement with Eisai, including working with Eisai and potential payments thereunder; regulatory review of lorcaserin, and Arena's response to the 120 day assessment; commercial and regulatory strategy and plans; Mr. Audet's role at Arena; financial guidance and related assumptions; lorcaserin's patents; and Arena's efforts, focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the pace of market acceptance; cash and revenues generated from BELVIQ, including timing and impact of competition; the timing and outcome of regulatory review is uncertain; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review, approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Arena Pharmaceuticals, Inc.Condensed Consolidated Statements of Operations (In thousands, except per share data)Three months endedSix months endedJune 30,June 30,2012201120122011(unaudited)(unaudited)RevenuesManufacturing services
$ 1,029$ 1,269$ 2,321$ 2,677Collaborative agreements
20,9481,99021,8454,507 Total revenues
21,9773,25924,1667,184Operating ExpensesCost of manufacturing services
6522,2771,4434,658Research and development
14,07614,70328,54630,638General and administrative
0003,467Amortization of acquired technology & other intangibles
173186349622 Total operating expenses
20,11723,24341,90952,352Interest and Other Income (Expense)Interest income
(2,489)(3,182)(5,520)(7,876)Gain (Loss) from valuation of derivative liabilities
(16,770)181(19,145)620Loss on extinguishment of debt
(57)443050 Total interest and other expense, net
(22,099)(22,908)(48,676)(62,806)Deemed dividend related to beneficial conversion feature
of convertible preferred stock
00(2,824)(2,260)Net loss allocable to common stockholders
$(22,099)$(22,908)$(51,500)$(65,066)Net loss per share allocable to common stockholders:Basic
(0.49)Shares used in calculating net loss per share allocable
to common stockholders:Basic
190,272142,693177,243132,232Arena Pharmaceuticals, Inc.Condensed Consolidated Balance Sheet Data(In thousands)June 30, 2012December 31, 2011(unaudited)1Assets Cash and cash equivalents
$ 143,811$ 57,632 Accounts receivable
20,578607 Other current assets
2,8632,021 Land, property & equipment, net
77,64282,066 Acquired technology & other non-current assets
$ 259,003$ 157,129Liabilities and Stockholders' Equity Accounts payable and accrued liabilities
$ 7,230$ 9,574 Total deferred revenues
47,91344,682 Total derivative liabilities
20,7621,617 Total note payable to Deerfield
014,698 Total lease financing obligations & other long-term liabilities
75,32375,996 Total stockholders' equity
107,77510,562Total liabilities & stockholders' equity
$ 259,003$ 157,1291 The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date.
Contact: Arena Pharmaceuticals, Inc.
Media Contact: Russo PartnersCindy McGee, Vice President
David Schull, PresidentInvestor Relations & Alliance Management
858.717.2310858.453.7200, ext. 1479
|SOURCE Arena Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved